XML 35 R21.htm IDEA: XBRL DOCUMENT
v3.8.0.1

License Agreements, Clinical Research Support Agreements and Sponsored Research Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2017
License Agreement Disclosure [Abstract] |
Research and Development Arrangement, Contract to Perform for Others [Table Text Block] | For the years ended December 31, 2017, 2016, and 2015 the Company recorded the following expense in research and development for licenses acquired:
|  | For the year ended December 31, |  | For the period from March 13, 2015 (Inception) to December 31, |
($ in thousands) |  | 2017 |  | 2016 |  | 2015 |
City of Hope |  |  |  |  |  |  |  |  |  |
CAR T |  | $ | - |  | $ | 1,683 |  | $ | 2,147 |
IL13Rα2 |  |  | 500 |  |  | - |  |  | - |
IV/ICV |  |  | 125 |  |  | - |  |  | - |
PSCA |  |  | 300 |  |  | - |  |  | - |
HER2 |  |  | 600 |  |  | - |  |  | - |
CS-1 |  |  | 600 |  |  | - |  |  | - |
Harvard University - CRISPR |  |  | 250 |  |  | - |  |  | - |
Fortress PIK Dividend |  |  | 9,558 |  |  | 4,396 |  |  | 190 |
UCLA - PSCA |  |  | 200 |  |  | - |  |  | - |
Fred Hutch - CD20 |  |  | 300 |  |  | - |  |  | - |
Total |  | $ | 12,433 |  | $ | 6,079 |  | $ | 2,337 |

X
- References No definition available. + Details
Name: | ck0001680048_LicenseAgreementDisclosureAbstract
Namespace Prefix: | ck0001680048_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements. Include also the amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. Include also the amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. Aggregation of similar arrangements by type may be appropriate. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration